fully agree... very well said, never had any "sucess", and this will also only see one direction (as in the past) and this is... down, down, down!

only my opinion!

and the whole "high caliber" board of directors at AMBS too!
the whole story was and is a scam!

only my oppinion...

looks like we are trading on the same level, but with the pipeline, I hope we will go up soon.

Ydream looks like a very interesting stock on the Canadian market. Very promissing product, very promissing customer... needs to be watched, i.m.o.!

I am with this stock since more than 2 years, but the only thing with GC is: "overpromissing and underdelivering"... that´s all.
It´s all the same since more than 2 years, wash, rinse, repeat!

Someone was saying "nothing has changed with the science", and that is absolutely true... "nothing has changed, no further development, no further achievement of Milestones, no deeper Information for shareholders....", absolutely nothing has changed!

Since the last time I bought in, I gained again a 67% Loss! So even this has not changed....

The NASDAQ uplist???? phhhhhhhh, do not see this in the near future. We all know that he needs a shareprice of more than 3$ for a certain time... with this decrease, the only thing that will happen is, this stock is going back to a penny stock... that´s it!

"MANF" is the development of his father and the Basis for this Company, and he will not destroy the lifetime achievement" ... he already did, cause not that much are still believe in GC´s words... all he is doing is a "blablabla" instead of being honest! That´s not a good Basis for trust... GC lost a lot of trust, confidence and credibility of us shareholders, and to be honest, I personally think that we could be further with another CEO, as GC is totally unexperienced and a fool. (yes I know that he has a University degree... blablabla, but what does this help? nothing!). He should better stick with sports instead of life science.

Of cause all said is only my opinion, do not want to force someone to by or sell!

which he doesn´t have!

now it Looks like ist going down, down, down....
I should have not buying in again... I should have known better from the past! Nothing happend from all GC has promised, and it Looks like this will continue! sad, sad... Only my thoughts

Regen BioPharma, Inc. Makes Three Presentations at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC
Regen Well Received at Conference, Resulting in Numerous Collaborative Opportunities

SAN DIEGO, CA--(Marketwired - May 5, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the Company has made presentations at 13th International Symposium on Myelodysplastic Syndromes held April 29 to May 2, 2015 in Washington, D.C.
Dr. Christine Ichim, Regen's Director of Molecular Therapeutics, made two oral presentations and one poster presentation at the conference:
1. "Technique for establishment of long term in vitro cultures of primary MDS cells" and
2. "NR2F6 (EAR-2) is a novel leukemia and MDS oncogene, over-expressed in patients, that inhibits hematopoietic differentiation and blocks erythropoietic differentiation at the proerythrocyte stage"
3. "HemaXellerate I™, Autologous adipose stromal vascular fraction cells, for severe aplastic anemia"
The subject of the first presentation was methods for growing myelodysplastic syndrome (MDS) cells in culture. "This is important as no one currently has been able to establish MDS cell lines. In this way, MDS is such a hard disease to treat since in vitro cells cannot be cultured for laboratory experiments. It is therefore impossible to conduct drug discovery and conduct research that unlocks the underlying biological mechanisms of this disease," according to Dr. Ichim, "Regen presented the first methodology for growing MDS cells in vitro, which positions the Company to be a leader in this field."
The subject of the second presentation was the discovery of gene NR2F6 as a drug target for differentiation therapy in treating leukemic and MDS patients suffering from anemia. This presentation showed that NR2F6 is a gene that both prevents the formation of red blood cells by blocking their differentiation and keeps them in a stem cell state.
The third presentation covered HemaXellerate as an autologous therapy for treating aplastic anemia. Regen presented the rational for the therapy and discussed HemaXellerate Investigational New Drug (IND) application which has been submitted to the USFDA.

A Company Spokesperson noted that, as a result of these presentations, Regen has been approached by numerous entities working in the area of MDS and Leukemia that are interested in possible future collaborations, co-development and other potential involvements with the Company.

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia. Regen is majority controlled by Bio-Matrix Scientific Group Inc. (OTC PINK: BMSN).
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Contact:

Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
www.regenbiopharma.com

got it, but was wondering what "third Extension granted" really mean? what´s behind this? any thoughts?

and what does this mean?

this all, according to the last 10K, doesn´t sound very promissing....

If you all remember what was promised last year:
--> uplisting to a national stock Exchange? failed!
--> commercializing LymPro Test in 2014? failed! now 1. Half 2015?
--> Milestone achievements in MANF? failed!

The more you now can read in the 10K "we have no product which is, or will be commercialized, if ever".... and I think, this is the truth... they will never commercialize anything, neither shortterm, nor longterm... this Company will bleed out... maybe a deadcat bounce some day, but that´s it!

All only my personal opinion, do not want to force anyone to sell or buy!

by the way, did someone heard anything about the presentation from yesterday?? any updates? any news??

cloveless, I am not able to send PM, so if you don´t mind send me one with details?

agreed, I do not expect too much this week too.

As in the past 16 months, the hype before a conference is high, but nothing really substantial happens.

I furthermore expect, that the shareprice will fall again...

Don´t get me wrong, I am invested since October 2012 with a bigger amount of shares, but I´ve seen the scenario above too oftenin the past.

I am confident, that the shareprive will increase soon, but do not expect this this week without esential news.

This is, as usual, only my feeling, not a recommendation to buy or sell!
cheers

agree

what have changed your mid? you were always so PRO AMBS, and now? what happend?

so folks, what is this for? :

http://www.trademarkia.com/dcellvax-86073736.html

any ideas?

listen. this stock is dead! 2 often dilluted in such incredible amounts.... and still al ot more to dillute! don´t ride a dead horse! only my opinion, nothing more, nothing less!

not as much as I do... and I saw and felt it badly last time, and I told you this time it would happen, don´t I?

but, you know we´ve had the same great expectations, and nearly the same increasing of shareprice before the investors update from Gerald iearlier this year... I do not expect too much, and I would not bet on that any annoncements or information or updates will follow this week.

As said before, patience is the key.
Obviously all is only MY opinion

I told you last time, and I will repeat my opinion again... I do know the company Brainlab and they are not into Biotech, they are into medical devices, especially in the area around treating cancer. I do know they have a few other subs working on different things, but I can not imagine that they will deal on one hand with medical devices with radiation as their core business, and on the other hand with a protein, that can easily destroy their core business...

simply, I can not imagine that they will do something like that, cause this will be a conflict of interest, if AMBS will partner with someone, they will search for someone in the pharma-business, but not in med.-tech for sure...

this is just my opinion, and as I am long with AMBS since last October, but I would be more than happy if I am wrong here
cheers

I remember your post that the chill lift should take place last week based on your information... now it is middle of this week? any thoughts?

I do not know, what you all are talking about... it is so easy to come to a figure based on the following:

The latest SEC filing (guess its the 13K) about shareholder structur is dated second of July 2013, Dominion Capital owns 7% of the common shares, and they state, that they own currently 25.776.845 shares.

So, it says, if 25Mio shares is 7% of the shares, the total amount of shares is??? Have a guess????? approx. 368Mio shares in total, so no dillution happend until beginning of July.

If so, the dillution must have take place after July 2nd, o.k.?

here you find the related link:
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204%2D13%2D037891%2Etxt&FilePath=%5C2013%5C07%5C02%5C&CoName=AMARANTUS+BIOSCIENCE+HOLDINGS%2C+INC%2E&FormType=SC+13G&RcvdDate=7%2F2%2F2013&pdf=

patinece is the key, strong and long!
of course all is only my opinion that must not be correct!

I realized that the LymPro Whitpaper on the amarantus hompeage is currently removed do to "updates", guess this is a good sign, what do you think about?

agree

don´t you get tired in re-posting the same things 10 times an hour? why don´t you by the dips and show us that you´re a serious investor? where is your BIG BOUNCES that you telling us since days and month?? cmon...

BrainLab is not a potential candidate for a JV as they are mainly in the area of cancer, so this has nothing to do with AMBS. I do know the company, and honestly, forget the thoughts about BrainLab.

So, why don´t you add then?

and this is the only thinf they have in common...

so, what does a buyout mean?